Apellis Pharmaceuticals, Inc. (APLS)

NASDAQ

$24.55

-$0.68 (2.68%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$24.47$25.56

Open $25.07

52 Week Range

$16.10$35.70

Previous Close $25.23

Market Cap3.11B

Volume2.25M

Avg Volume2.60M

P/E (TTM)68.79

EPS (TTM)$0.36

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Apellis Pharmaceuticals, Inc.

DEC32025

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Source: GlobeNewsWire•12 days ago

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase 3 VALIANT study investigating EMPAVELI® (pegcetac...

NOV252025

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Source: GlobeNewsWire•20 days ago

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Citi's 2025 Global Healthcare Conference ...

NOV122025

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

Source: GlobeNewsWire•33 days ago

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injecti...

NOV52025

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

Source: GlobeNewsWire•40 days ago

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET....

OCT302025

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Source: GlobeNewsWire•46 days ago

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights....

OCT202025

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Source: GlobeNewsWire•56 days ago

WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacopl...

OCT162025

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Source: GlobeNewsWire•60 days ago

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webc...